Monopar Therapeutics MNPR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $3.49M+112% | $3.94M-60.3% | $2.59M+163% | $1.73M+53.0% | $1.64M+70.1% | ||
| $1.74M+10.1% | $2.21M+92.5% | $1.5M+155% | $1.5M+129% | $1.58M+108% | ||
| $5.23M+62.2% | $6.16M-44.4% | $4.09M+160% | $3.23M+80.8% | $3.22M+86.9% | ||
| $5.23M+62.2% | $6.16M-44.4% | $4.09M+160% | $3.23M+80.8% | $3.22M+86.9% | ||
| -$5.23M-62.2% | -$6.16M+44.4% | -$4.09M-160% | -$3.23M-80.8% | -$3.22M-86.9% | ||
| $1.33M+123% | $954.43K+540% | $655.47K+560% | $780.77K+963% | $596.85K+626% | ||
| -$3.89M-48.3% | -$5.2M+52.4% | -$3.44M-164% | -$2.45M-43.0% | -$2.62M-59.9% | ||
| -$0.46-21.1% | -$0.64+76.7% | -$0.48-29.7% | -$0.35+28.6% | -$0.38+25.5% | ||
| 8.5M+22.2% | 7.4M+95.5% | 7.1M+102% | 7M+99.8% | 7M+119% | ||
| -$3.93M-49.7% | -$5.08M+53.3% | -$3.5M-165% | -$2.35M-37.6% | -$2.62M-61.7% | ||
| -$190-115% | -$226— | -$116-102% | -$3.46K-318% | $1.24K+248% | ||
| -$32.68K-9,545% | $119.92K+134% | -$65.76K-169% | $102.82K+4,107% | $346-98.2% | ||
| -$5.23M-62.2% | -$6.16M+44.4% | -$4.09M-160% | -$3.23M-80.8% | -$3.22M-86.9% | ||
| -$5.23M-62.2% | -$6.16M+44.4% | -$4.09M-160% | -$3.23M-80.8% | -$3.22M-86.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Monopar Therapeutics profitable?
- Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.
- Where does Monopar Therapeutics's income statement data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.